Key result
Dabigatran is linked to spontaneous choroidal hemorrhage in a single AF case report.
Why the study?
Dabigatran etexilate is a new alternative to warfarin with no blood monitoring or reversal agent, and its possible hemorrhagic complications are not well documented.
Does dabigatran etexilate cause spontaneous choroidal hemorrhage in patients with atrial fibrillation?
Case Report (n=1)
Does dabigatran etexilate cause spontaneous choroidal hemorrhage in patients with atrial fibrillation?
This first reported case of spontaneous choroidal hemorrhage associated with dabigatran highlights a potential severe hemorrhagic complication of the drug.
Answers are grounded in this paper and cite their sources.
Possible dabigatran choroidal hemorrhage warrants clinical awareness; single case leaves open causality in AF.
In Brief Purpose: To report the first known case of spontaneous choroidals in association with a patient on dabigatran etexilate. Methods: Observational case report. Results: An 82-year-old man on 150 mg dabigatran etexilate by mouth twice a day for atrial fibrillation developed spontaneous choroidal hemorrhage in his left eye. No other causes were found after careful history and examination. Conclusion: Dabigatran is a popular new alternative to warfarin that has no blood monitoring or reversal agent. Physicians should be aware of this new medication and its possible hemorrhagic complications. Dabigatran is a popular new alternative to warfarin that has no blood monitoring or reversal agent. Physicians should be aware of this new medication and its possible hemorrhagic complications.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2014) conducted a case report in Atrial fibrillation (n=1). Dabigatran etexilate was evaluated on Spontaneous choroidal hemorrhage. Dabigatran etexilate therapy in 1 patient with atrial fibrillation was associated with the development of a spontaneous choroidal hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: